{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:45:11Z","timestamp":1792755911390,"version":"4.5.0"},"reference-count":39,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1045235"],"award-info":[{"award-number":["1045235"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1028326"],"award-info":[{"award-number":["1028326"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1099278"],"award-info":[{"award-number":["1099278"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Due to the continuing emergence of multidrug resistant strains of Neisseria gonorrhoeae there is an urgent need for the development of a gonococcal vaccine. We evaluated the gonococcal Neisseria heparin binding antigen (NHBA) as a potential vaccine candidate, in terms of its sequence conservation and expression in a range of N. gonorrhoeae strains, as well as its immunogenicity and the functional activity of antibodies raised to either the full length NHBA or a C-terminal fragment of NHBA (NHBA-c). The gene encoding NHBA is highly conserved and expressed in all N. gonorrhoeae strains investigated. Recombinant NHBA is immunogenic, and mice immunized with either NHBA or NHBA-c adjuvanted with either Freund\u2019s or aluminium hydroxide (alum) generated a humoral immune response, with predominantly IgG1 antibodies. Antibodies generated by both NHBA and NHBA-c antigens promoted complement activation and mediated bacterial killing via both serum bactericidal activity and opsonophagocytic activity, with slightly higher titers seen for the NHBA-c antigen. Anti-NHBA was also able to block the functional activity of NHBA by reducing binding to heparin and adherence to cervical and urethral epithelial cells. These data suggest that the gonococcal NHBA is a promising vaccine antigen to include in a vaccine to control N. gonorrhoeae.<\/jats:p>","DOI":"10.3390\/vaccines8020219","type":"journal-article","created":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T10:27:19Z","timestamp":1589452039000},"page":"219","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["The Neisseria gonorrhoeae Vaccine Candidate NHBA Elicits Antibodies That Are Bactericidal, Opsonophagocytic and That Reduce Gonococcal Adherence to Epithelial Cells"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5188-7946","authenticated-orcid":false,"given":"Evgeny A.","family":"Semchenko","sequence":"first","affiliation":[{"name":"Institute for Glycomics, Griffith University, Gold Coast 4215, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Day","sequence":"additional","affiliation":[{"name":"Institute for Glycomics, Griffith University, Gold Coast 4215, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7094-3528","authenticated-orcid":false,"given":"Kate L.","family":"Seib","sequence":"additional","affiliation":[{"name":"Institute for Glycomics, Griffith University, Gold Coast 4215, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1473-3099(18)30340-2","article-title":"Genetic characterisation of Neisseria gonorrhoeae resistant to both ceftriaxone and azithromycin","volume":"18","author":"Whiley","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_2","unstructured":"European Centre for Disease Prevention and Control (2020, April 08). Extensively Drug-Resistant (XDR) Neisseria Gonorrhoeae in the United Kingdom and Australia. Available online: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/rapid-risk-assessment-extensively-drug-resistant-xdr-neisseria-gonorrhoeae-united."},{"key":"ref_3","unstructured":"(2020, April 08). Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. Available online: http:\/\/www.who.int\/medicines\/publications\/global-priority-list-antibiotic-resistant-bacteria\/en\/."},{"key":"ref_4","unstructured":"(2020, April 08). Centre for Disease Control and Prevention, Available online: http:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/pdf\/ar-threats-2013-508.pdf."},{"key":"ref_5","unstructured":"Department of Health (2015). Responding to the Threat of Antimicrobial Resistance: Australia\u2019s First National Antimicrobial Resistance Strategy 2015\u20132019."},{"key":"ref_6","unstructured":"World Health Organisation (2020, March 07). Global Incidence and Prevalence of Selected Curable Sexually Transmitted Infections\u20142008. Available online: http:\/\/www.who.int\/reproductivehealth\/publications\/rtis\/stisestimates\/en\/."},{"key":"ref_7","unstructured":"CDC (2020, March 07). Sexually Transmitted Disease Surveillance 2017, Available online: https:\/\/www.cdc.gov\/std\/stats 2018."},{"key":"ref_8","unstructured":"Kirby Institute (2018). HIV, viral hepatitis and sexually transmissible infections in Australia: Annual surveillance report 2018, The Kirby Institute."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3109\/1040841X.2015.1105782","article-title":"Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development","volume":"42","author":"Edwards","year":"2016","journal-title":"Crit. Rev. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1146\/annurev-micro-090816-093530","article-title":"Neisseria gonorrhoeae: Drug Resistance, Mouse Models, and Vaccine Development","volume":"71","author":"Rice","year":"2017","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(17)31449-6","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: A retrospective case-control study","volume":"390","author":"Paynter","year":"2017","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/cid\/ciy1061","article-title":"The serogroup B meningococcal vaccine Bexsero elicits antibodies to Neisseria gonorrhoeae","volume":"69","author":"Semchenko","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"B87","DOI":"10.1016\/j.vaccine.2012.01.033","article-title":"The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigens","volume":"30","author":"Serruto","year":"2012","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"41767","DOI":"10.1074\/jbc.M111.289314","article-title":"Structure of the C-terminal domain of Neisseria heparin binding antigen (NHBA), one of the main antigens of a novel vaccine against Neisseria meningitidis","volume":"286","author":"Esposito","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6512","DOI":"10.1038\/s41598-018-24639-x","article-title":"The Bexsero Neisseria meningitidis serogroup B vaccine antigen NHBA is a high-affinity chondroitin sulfate binding protein","volume":"8","author":"Mubaiwa","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1073\/pnas.0915162107","article-title":"Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans","volume":"107","author":"Serruto","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Vacca, I., Del Tordello, E., Gasperini, G., Pezzicoli, A., Di Fede, M., Rossi Paccani, S., Marchi, S., Mubaiwa, T.D., Hartley-Tassell, L.E., and Jennings, M.P. (2016). Neisserial Heparin Binding Antigen (NHBA) Contributes to the Adhesion of Neisseria meningitidis to Human Epithelial Cells. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0162878"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Maritan, M., Veggi, D., Cozzi, R., Dello Iacono, L., Bartolini, E., Lo Surdo, P., Maruggi, G., Spraggon, G., Bottomley, M.J., and Malito, E. (2018). Structures of NHBA elucidate a broadly conserved epitope identified by a vaccine induced antibody. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0201922"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1107\/S2053230X17006021","article-title":"Crystal structures of human Fabs targeting the Bexsero meningococcal vaccine antigen NHBA","volume":"73","author":"Maritan","year":"2017","journal-title":"Acta Crystallogr. F. Struct. Biol. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","article-title":"Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing","volume":"287","author":"Pizza","year":"2000","journal-title":"Science"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1086\/379375","article-title":"Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity","volume":"188","author":"Welsch","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1128\/CVI.00036-08","article-title":"Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B","volume":"15","author":"Plested","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1073\/pnas.1321556111","article-title":"Neisseria meningitidis NalP cleaves human complement C3, facilitating degradation of C3b and survival in human serum","volume":"111","author":"Vacca","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e00163-13","DOI":"10.1128\/mBio.00163-13","article-title":"Conservation of meningococcal antigens in the genus Neisseria","volume":"4","author":"Muzzi","year":"2013","journal-title":"Mbio"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Semchenko, E.A., Mubaiwa, T.D., Day, C.J., and Seib, K.L. (2019). The gonococcal Neisserial Heparin Binding Antigen (NHBA) is involved in microcolony formation and contributes to serum resistance and adherence to epithelial cells. J. Infect. Dis., 10.","DOI":"10.1093\/infdis\/jiz628"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1086\/593336","article-title":"Gonococcal cervicitis: A role for biofilm in pathogenesis","volume":"198","author":"Steichen","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Jen, F.E.C., Semchenko, E.A., Day, C.J., Seib, K.L., and Jennings, M.P. (2019). The Neisseria gonorrhoeae Methionine Sulfoxide Reductase (MsrA\/B) Is a Surface Exposed, Immunogenic, Vaccine Candidate. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00137"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Semchenko, E.A., Day, C.J., and Seib, K.L. (2017). MetQ of Neisseria gonorrhoeae Is a Surface-Expressed Antigen That Elicits Bactericidal and Functional Blocking Antibodies. Infect. Immun., 85.","DOI":"10.1128\/IAI.00898-16"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.4049\/jimmunol.1701666","article-title":"Human Factor H Domains 6 and 7 Fused to IgG1 Fc Are Immunotherapeutic against Neisseria gonorrhoeae","volume":"201","author":"Shaughnessy","year":"2018","journal-title":"J. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1086\/595737","article-title":"Thioredoxin reductase is essential for protection of Neisseria gonorrhoeae against killing by nitric oxide and for bacterial growth during interaction with cervical epithelial cells","volume":"199","author":"Potter","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.1128\/IAI.70.10.5808-5815.2002","article-title":"Immortalization of human urethral epithelial cells: A model for the study of the pathogenesis of and the inflammatory cytokine response to Neisseria gonorrhoeae infection","volume":"70","author":"Harvey","year":"2002","journal-title":"Infect. Immun."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Rajam, G., Stella, M., Kim, E., Paulos, S., Boccadifuoco, G., Serino, L., Carlone, G., and Medini, D. (2017). Meningococcal Antigen Typing System (MATS)-Based Neisseria meningitidis Serogroup B Coverage Prediction for the MenB-4C Vaccine in the United States. mSphere, 2.","DOI":"10.1128\/mSphere.00261-17"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1016\/j.vaccine.2017.06.020","article-title":"The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C","volume":"35","author":"Partridge","year":"2017","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1128\/IAI.00891-10","article-title":"Characterization of Diverse Subvariants of the Meningococcal Factor H (fH) Binding Protein for Their Ability To Bind fH, To Mediate Serum Resistance, and To Induce Bactericidal Antibodies","volume":"79","author":"Seib","year":"2011","journal-title":"Infect. Immun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1128\/IAI.02984-14","article-title":"Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity","volume":"83","author":"Giuntini","year":"2015","journal-title":"Infect. Immun."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Zhu, T., McClure, R., Harrison, O.B., Genco, C., and Massari, P. (2019). Integrated Bioinformatic Analyses and Immune Characterization of New Neisseria gonorrhoeae Vaccine Antigens Expressed during Natural Mucosal Infection. Vaccines (Basel), 7.","DOI":"10.3390\/vaccines7040153"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00007435-200110000-00001","article-title":"Experimental gonococcal urethritis and reinfection with homologous gonococci in male volunteers","volume":"28","author":"Schmidt","year":"2001","journal-title":"Sex Transm. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.0300-9475.2004.01362.x","article-title":"The four mouse IgG isotypes differ extensively in bactericidal and opsonophagocytic activity when reacting with the P1.16 epitope on the outer membrane PorA protein of Neisseria meningitidis","volume":"59","author":"Michaelsen","year":"2004","journal-title":"Scand J. Immunol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/2\/219\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:28:32Z","timestamp":1760174912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/2\/219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,13]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["vaccines8020219"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8020219","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,13]]}}}